https://www.live-feeds.com/feed/johnson-johnson-stock-falls-despite-strong-earnings-as-investors-focus-on-medtech-unitContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/johnson-johnson-stock-falls-despite-strong-earnings-as-investors-focus-on-medtech-unithttps://www.live-feeds.com/feed/johnson-johnson-stock-falls-despite-strong-earnings-as-investors-focus-on-medtech-unit#u135958Mon, 19 Oct 2026 13:15:52 +0000Johnson & Johnson shares dropped over 5% following its third-quarter earnings report despite beating forecasts with earnings of $2.59 per share and raising its 2026 guidance. Total quarterly sales rose 5.9% to $25.4 billion, driven by pharmaceutical growth. However, the selloff occurred because MedTech sales grew just 2.5% to $8.64 billion, missing expectations and overshadowing the positive pharmaceutical results. Investors weighed the valuation against growth risks, focusing heavily on the medical technology underperformance.Why it mattersThe stock decline highlights how weakness in the